Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2024-05-24 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2024年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年第二次临时股东大会会议资料" which translates to "2024 Second Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed information about the meeting agenda, voting procedures, and a specific proposal regarding the absorption merger of a wholly-owned subsidiary and a wholly-owned sub-subsidiary, including financial data and legal compliance. The content is clearly materials prepared for the shareholders to review before or during the EGM. It is not a report of voting results, nor a brief announcement, but rather the meeting materials themselves. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary ones). The document length (5946 characters) and detailed content confirm it is the meeting materials, not just an announcement or voting results. Therefore, the correct classification is AGM Information (AGM-R).
2024-05-24 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司2023年年度股东大会的法律意见
Regulatory Filings Classification · 90% confidence The document text consists solely of placeholders indicating omitted pictures, with no textual content or substantive information. The total character count is 2065, which is under 5000 characters, and there is no actual report content or financial data present. This suggests the document is not a full report but likely an announcement or placeholder. Given the lack of any textual report or data, and the presence of only images (which are omitted), the best classification is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2024-05-16 Chinese
华泰联合证券有限责任公司关于普莱柯全资子公司吸收合并全资孙公司暨变更部分募投项目实施主体的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd., acting as the sponsor for Pulike Bioengineering Co., Ltd. It concerns the absorption merger of a wholly-owned subsidiary by a wholly-owned sub-subsidiary and the change of the implementation subject of part of the raised investment projects. The document includes detailed company background, financial data, merger arrangements, fundraising details, board and supervisory opinions, and the sponsor's verification opinion. It references regulatory compliance and approvals related to a non-public stock issuance in 2022. The document is not a full annual or interim report, nor is it a simple announcement or certification. It is a formal verification opinion related to a financing and corporate restructuring event, which aligns with a Capital/Financing Update (CAP) filing type. The length and detail confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2024-05-16 Chinese
普莱柯关于第五届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the eighth meeting of the fifth Supervisory Board of 普莱柯生物工程股份有限公司. It details the meeting date, attendance, and the voting results on a specific corporate action involving the absorption merger of a wholly-owned subsidiary and changes in the implementation subject of a fundraising project. The document is an official announcement of board-level decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or a report publication notice. The content fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management bodies.
2024-05-16 Chinese
普莱柯2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of 普莱柯生物工程股份有限公司, including voting results on various proposals such as the annual report, board work report, financial statements, profit distribution, appointment of auditors, and remuneration of directors and senior management. It includes meeting attendance, voting percentages, and legal witness statements confirming the validity of the meeting and resolutions. The document is not the annual report itself but the official announcement of the AGM resolutions and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting data, confirming it is not a mere brief notice or report publication announcement.
2024-05-16 Chinese
普莱柯关于第五届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 普莱柯生物工程股份有限公司 regarding resolutions passed at the 12th meeting of the 5th board. It details the meeting date, attendance, and voting results on several proposals including a merger, organizational restructuring, and calling a shareholders meeting. The content focuses on board decisions and governance matters rather than financial results or reports. There is no indication of financial statements or earnings data. The document is not a report itself but an announcement of board resolutions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and it is a formal announcement of board decisions, fitting the MANG category with high confidence.
2024-05-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.